Table 2 Comparison of 32 BC infected HSCT patients with and without respiratory failure
Characteristic | Without RF (n = 21) | With RF (n = 11) | P-value |
|---|---|---|---|
Age, years, meidan (IQR) | 14 (7, 47) | 14 (7, 30) | 0.968 |
Gender, n (%) | 0.374 | ||
 Male | 15 (71.4) | 10 (90.9) |  |
 Female | 6 (28.6) | 1 (9.1) |  |
Infection site, n (%) | 0.681 | ||
 Pulmonary infection | 15 (71.4) | 9 (81.8) |  |
 Bloodstream infection | 6 (28.6) | 2 (18.2) |  |
CMV infection before transplantation, n (%) | 7 (33.3) | 5 (45.5) | 0.703 |
Use of broad-spectrum antibiotics > 5 days 1 month prior to infection, n (%) | 19 (90.5) | 9 (81.8) | 0.593 |
HLA identical match, n (%) | 15 (71.4) | 5 (45.5) | 0.250 |
Mesenchymal stem cell infusion, n (%) | 4 (19) | 0 (0) | 0.272 |
Hematopoietic reconstruction time > 15 days, n (%) | 8 (38.1) | 6 (54.5) | 0.465 |
aGVHD, n (%) | 15 (71.4) | 10 (90.9) | 0.374 |
Indicators of initial stage of infection | |||
 Neutrophil count, 109/L, median (IQR) | 1.6 (0.90, 2.00) | 3.4 (1.10, 8.80) | 0.196 |
 Platelet count, 109/L, median (IQR) | 33 (23.00, 41.00) | 46 (33.00, 151.00) | 0.256 |
 PCT, µg/L, median (IQR) | 0.67 (0.20, 2.16) | 34.29 (0.05, 55.21) | 0.349 |
 Albumin, g/L, median (IQR) | 35.6 (31.30, 37.10) | 29 (29.00, 36.90) | 0.735 |
 Total bilirubin, µmol/L, median (IQR) | 13.8 (9.20, 36.00) | 9.5 (7.30, 11.90) | 0.064 |
 Creatinine, µmol/L, median (IQR) | 47 (43.80, 98.00) | 84 (41.8, 98.00) | 0.511 |
Irrational empiric anti-infective therapy, n (%) | 5 (23.8) | 5 (45.5) | 0.252 |
Admission to ICU after transplantation, n (%) | 9 (42.9) | 11 (100) | 0.002* |
Renal replacement therapy, n (%) | 3 (14.3) | 5 (45.5) | 0.088 |
Septic shock, n (%) | 5 (23.8) | 9 (81.8) | 0.003* |
Mortality, n (%) | 8 (38.1) | 10 (90.9) | 0.008* |